FDA Adverse Event Malfunction Summary report: N

ARCHITECT STAT TROPONIN-I

MDR report key: 1812818 · Received August 24, 2010

Report

Report Number
1415939-2010-00395
Event Type
Malfunction
Date Received
August 24, 2010
Date of Event
July 26, 2010
Report Date
August 3, 2010
Manufacturer
ABBOTT LABORATORIES
Product Code
MMI
PMA / PMN Number
K041192
Product Problem
Yes
Report Source
Manufacturer report
Reporter Location
AU
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

(B)(4). A FOLLOW-UP REPORT WILL BE SUBMITTED WHEN THE INVESTIGATION IS COMPLETE.

Additional Manufacturer Narrative · 1

(B)(4). AN INVESTIGATION WAS INITIATED TO FURTHER INVESTIGATE THE CUSTOMER ISSUE INCLUDING A REVIEW OF THE COMPLAINT TEXT, TESTING OF RETURNED MATERIAL AND PANEL TESTING, A SEARCH FOR SIMILAR COMPLAINTS, AND A REVIEW OF LABELING. PATIENT SAMPLE (B)(6) WAS TESTED UNDILUTED USING A FILE KIT OF THE SAME LOT NUMBER AS THE CUSTOMER'S LOT. AN EXPECTED, NEGATIVE RESULT OF 0.01 NG/ML WAS OBTAINED. AN INTERNAL TROPONIN-I PANEL WAS ALSO TESTED AND RESULTS WERE WITHIN SPECIFICATION. TRACKING AND TRENDING DID NOT INDICATE ANY ADVERSE TREND FOR THE COMPLAINT ISSUE. LABELING WAS REVIEWED AND FOUND TO BE ADEQUATE. BASED ON THE INVESTIGATION, NO PRODUCT ISSUE WAS IDENTIFIED FOR FALSE POSITIVE ARCHITECT TROPONIN-I RESULTS.

Description of Event or Problem · 1

THE CUSTOMER STATED AN ARCHITECT I2000SR ANALYZER GENERATED A FALSE POSITIVE TROPONIN RESULT FOR ONE PATIENT SAMPLE. THE SAMPLE GENERATED AN INITIAL TROPONIN RESULT OF 0.661 NG/ML AND A REPEAT TROPONIN RESULT OF 0.000 NG/ML. THE FALSELY ELEVATED TROPONIN RESULT WAS NOT REPORTED OUTSIDE THE LABORATORY AND THERE WAS NO ADVERSE IMPACT TO PATIENT MANAGEMENT REPORTED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 ARCHITECT STAT TROPONIN-I FOR THE DETERMINATION OF CARDIAC TROPONIN-I IN HUMAN SERUM OR PLASMA MMI ABBOTT LABORATORIES 39419UN10

Patients

Seq Age Sex Outcome Treatment
1 ARCH I2000SR LN 3M74-01 (B)(4)| ARCH I2000SR LN 3M74-01 (B)(4)